Sara Samadzadeh
Overview
Explore the profile of Sara Samadzadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan F, Berhanu D, Samadzadeh S, Francis A, Asgari N, Paul F, et al.
Mult Scler
. 2025 Mar;
:13524585251325069.
PMID: 40088045
Background: Smoking and vascular risk factors (VRFs) are reported to have adverse effects in multiple sclerosis but data are limited in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin...
2.
Ricigliano V, Marenna S, Borrelli S, Camera V, Carnero Contentti E, Szejko N, et al.
Biomedicines
. 2025 Feb;
13(2).
PMID: 40002770
Multiple sclerosis (MS) pathology is characterized by acute and chronic inflammation, demyelination, axonal injury, and neurodegeneration. After decades of research into MS-related degeneration, recent efforts have shifted toward recovery and...
3.
Hefter H, Rosenthal D, Samadzadeh S
J Funct Morphol Kinesiol
. 2025 Feb;
10(1).
PMID: 39982280
Botulinum neurotoxin type A (BoNT/A) injections and the new vibration ergometry training (VET) are studied for their combined effect on improving functional mobility in patients with asymmetric lower limb spasticity....
4.
Samadzadeh S, Sleator R
eNeurologicalSci
. 2025 Jan;
38:100550.
PMID: 39866832
Fluid biomarkers such as Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light (NfL) play important roles in the diagnosis, monitoring, and evaluation of therapeutic responses in conditions such as Multiple...
5.
Hefter H, Samadzadeh S
J Clin Med
. 2025 Jan;
14(2).
PMID: 39860486
Repetitive intramuscular injections of botulinum neurotoxin (BoNT) have become the treatment of choice for a variety of disease entities. But with the onset of BoNT therapy, the natural course of...
6.
Hefter H, Moll M, Samadzadeh S
Toxins (Basel)
. 2024 Nov;
16(11).
PMID: 39591243
There is some evidence that injections of botulinum neurotoxin effectively reduce pain in complex regional pain syndromes (CRPSs). But no or little experience appears to exist for the application of...
7.
Adnan R, Roikjaer S, Samadzadeh S, Richter C, Weinshenker B, Paul F, et al.
Front Neurol
. 2024 Oct;
15:1449519.
PMID: 39474367
Introduction: Physical exercise (PE) improves symptoms and quality of life in people with multiple sclerosis (pwMS). However, incorporating PE into daily lives of pwMS pose difficulties. As an alternative to...
8.
Abolfazli R, Nabavi S, Azimi A, Nahayati M, Gharagozli K, Torabi H, et al.
Clin Neurol Neurosurg
. 2024 Sep;
246:108552.
PMID: 39270462
Background: Patient-reported outcomes (PROs) provide valuable insights into the impact of disease-modifying therapies (DMTs) on patients' daily lives and disease progression. This study evaluates treatment satisfaction and tolerability among patients...
9.
Etemadifar M, Alaei S, Akaishi T, Salari M, Norouzi M, Samadzadeh S, et al.
Mult Scler Relat Disord
. 2024 Sep;
90:105843.
PMID: 39217808
Introduction: Neuromyelitis Optica Spectrum Disorders (NMOSD) is a neuroinflammatory condition characterized by optic neuritis and transverse myelitis. While the current approach to NMOSD focuses on relapse-associated worsening (RAW), recent evidence...
10.
Samadzadeh S, Adnan R, Berglova P, Barzegar M, Debrabant B, Roikjaer S, et al.
Front Immunol
. 2024 Jul;
15:1380025.
PMID: 39021565
Comorbidities in patients with multiple sclerosis (MS) and antibody-mediated diseases of the central nervous system (CNS) including neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease (MOGAD) are...